How well patients stick to aromatase inhibitor treatment, with or without abemaciclib, for early HR+/HER2- breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational study comparing medication adherence and treatment persistence between patients taking adjuvant aromatase inhibitors alone and those taking aromatase inhibitors together with abemaciclib. Participants are women with early HR+/HER2- breast cancer receiving adjuvant therapy for up to 18 months at the Institute of Oncology Ljubljana. The study will relate adherence and discontinuation rates to patient-reported measures such as quality of life, cognitive function, and attitudes toward therapy, as well as demographic and treatment history factors. Findings aim to clarify whether the addition of abemaciclib, with its distinct safety profile, is associated with different real-world adherence patterns.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Female,
* Early HR+/HER-2- BC,
* Patient is receiving adjuvant therapy with an aromatase inhibitor (letrozole, anastrozole or exemestane), with or without a CDK4/6 inhibitor abemaciclib, for no more than 18 months,
* Treatment of BC is being conducted at OIL,
* Patient has mandatory health insurance through Health Insurance Institute of Slovenia,
* Patient understands Slovenian language, and
* Patient agrees to participate in the study and provides written informed consent.

Exclusion Criteria:

* Metastatic HR+/HER2-negative breast cancer
* Previous treatment for breast cancer with an aromatase inhibitor, with or without a CDK4/6 inhibitor, for early breast cancer prior to the current adjuvant treatment line

Where it's running

• Institute of Oncology Ljubljana
  Ljubljana, Slovenia Recruiting

Study contacts

• Principal investigator: Erika Matos, PhD — Institute of Oncology Ljubljana, Slovenia
• Study coordinator: Erika Matos, PhD
• Email: ematos@onko-i.si
• Phone: 00386 1 5879 715

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Giredestrant in ER-positive, HER2-negative early breast cancer: who tolerates it and sticks with treatment

  This study tests how well people with ER-positive, HER2-negative early breast cancer can tolerate and stay on giredestrant, and how they feel during treatment.

  Recruiting Phase 3 Hoffmann-La Roche · Québec, Quebec · NCT07827573

• RGT-490 for adults with PIK3CA-mutated advanced solid tumors

  This trial will test RGT-490, an oral medicine, in adults whose advanced solid tumors carry a PIK3CA mutation and have progressed after prior therapy.

  Recruiting at 6 sites Phase 1 Regor Pharmaceuticals Inc. · Los Angeles, California and 5 other locations · NCT07524322

• TheraBionic P1 device in advanced HR-positive, HER2-negative breast cancer

  This trial tests whether the TheraBionic P1 device can help women with advanced or metastatic HR-positive, HER2-negative breast cancer who have progressed on standard therapies, by looking at survival and disease control.

  Recruiting at 8 sites Barbara Ann Karmanos Cancer Institute · Bay City, Michigan and 7 other locations · NCT07227831

• Adding TheraBionic P1 radiofrequency therapy to treatment for early-stage HR+ HER2- breast cancer

  This study will try giving TheraBionic P1 amplitude-modulated radiofrequency therapy before surgery to see if it improves tumor response in women with early-stage, hormone receptor–positive, HER2-negative breast cancer.

  Recruiting at 8 sites Barbara Ann Karmanos Cancer Institute · Clarkston, Michigan and 7 other locations · NCT07218432

• RLY-2608 plus fulvestrant versus capivasertib plus fulvestrant for PIK3CA‑mutant HR+/HER2‑ advanced breast cancer

  This trial tests whether RLY-2608 combined with fulvestrant works better than capivasertib combined with fulvestrant for adults with HR+/HER2‑ advanced breast cancer that has a PIK3CA mutation and progressed after a CDK4/6 inhibitor.

  Recruiting at 254 sites Phase 3 Relay Therapeutics, Inc. · Gilbert, Arizona and 253 other locations · NCT06982521

• Elacestrant alone or with triptorelin for premenopausal luminal (HR+/HER2−) breast cancer

  This trial will test whether the oral drug elacestrant, given alone or with triptorelin (and compared to tamoxifen in Part B), changes tumor biology in premenopausal women with operable hormone receptor–positive, HER2‑negative breast cancer.

  Recruiting at 15 sites Phase 2 SOLTI Breast Cancer Research Group · Badalona, Barcelona and 14 other locations · NCT05982093

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.